After 20 years, the clean-in-place (CIP) operations in Building B at Emergent Biosolution’s Winnipeg, Canada, facility were ready for retirement. Built in the early 1990s, the systems had reached their life expectancy and were now out of date. Building B manufactures human hyper-immune plasma products such as Anthrasil [anthrax immune globulin intravenous (human)], VIG (vaccinia…